Prognose

Analytikernes gennemsnitlige kursmål er 16,18 € (+42,68 %). Medianen er 16,47 € (+45,24 %).

Køb	11
Behold	3
Sælg	1

Nyheder Til nyhedsfeedet

Replimune starts cautious rollout of TujuCare after FDA approval

After FDA approval of TujuCare for advanced melanoma, Replimune outlines a cautious, staged launch, initially with 200 first‑user centers and 70% of the commercial team already hired. The list price is $450,000 per patient based on the median use in the IGNYTE study, though early revenue is likely to be dampened by an initially lower dose and training and reimbursement efforts. The company is launching with a temporary J‑code and expects acceleration in Q3–Q4; manufacturing costs are estimated at about 10% of revenue. Replimune is also advancing a broad pipeline, including RP2 for metastatic uveal melanoma (REVEAL study) and the confirmatory IGNYTE‑3 study, which is still recruiting and aimed at readout by 2030. » Mere på de.investing.com
Replimune Group reaches new 52-week high at $16.20

Replimune Group’s stock rose to a 52-week high of $16.20, well above its yearly low of $1.50. Over the past year the price climbed about 166%, roughly 119% in the last six months and around 61% year-to-date. Analysts consider the stock above its fair value, citing price targets between $14 and $24, and several firms raised their estimates after the accelerated FDA approval of Tudriqev in combination with Nivolumab. » Mere på de.investing.com
Replimune Group reaches 52-week high after FDA approval of Tudriqev

Replimune Group’s stock rose to a 52-week high of $15.72 and is currently trading at $15.69, implying a market capitalization of about $1.47 billion. Over the past year the share gained 174.3%, while InvestingPro warns the stock may currently be trading above its fair value. Options data suggest a potential price move of roughly 5.6% ahead of the quarterly results. Several analysts (Wedbush, Leerink, Cantor Fitzgerald) raised their valuations following the FDA approval of Tudriqev and positive prospects for RP-1 in combination with nivolumab. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Replimune Group en omsætning på 0 € og et nettoresultat på -61,13 mio. €

(EUR)	juni 2026	YoY
Omsætning	0	-
Bruttofortjeneste	0	-
Nettoresultat	-61,13 mio.	16,89 %
EBITDA	-57,85 mio.	23,75 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	941 mio. €
Antal aktier	84,03 mio.
Højeste/laveste i 52 uger	14,15 € - 1,30 €
Udbytte	Nej
Beta	0,94
P/E (PE Ratio)	-4,10
PEG (PEG Ratio)	-0,68
K/I (PB Ratio)	11,85
P/S (PS Ratio)	0,00

Virksomhedsprofil

Die Replimune Group, Inc. ist ein Biotechnologieunternehmen, das onkolytische Immuno-Gentherapien zur Behandlung von Krebs entwickelt. Es nutzt seine firmeneigene Immuntherapie-Plattform, um Produktkandidaten zu entwerfen und zu entwickeln, die das Immunsystem gegen Krebs aktivieren sollen. Der führende Produktkandidat des Unternehmens ist RP1, eine selektiv replizierende Version des Herpes-Simplex-Virus 1, die sich in klinischen Studien der Phase I/II für eine Reihe von soliden Tumoren und in klinischen Studien der Phase II für Patienten mit Plattenepithelkarzinomen der Haut befindet. Darüber hinaus entwickelt das Unternehmen RP2, das sich in der klinischen Phase I für ein Anti-CTLA-4-Antikörper-ähnliches Protein befindet, um die Hemmung der Immunantwort zu blockieren, die ansonsten durch CTLA-4 verursacht wird, sowie RP3, das sich in der klinischen Phase I befindet, um immunaktivierende Proteine zu exprimieren, die T-Zellen stimulieren. Die Replimune Group, Inc. wurde 2015 gegründet und hat ihren Hauptsitz in Woburn, Massachusetts.